Rice Hall James & Associates LLC Has $14.27 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Rice Hall James & Associates LLC lessened its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 8.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,880,389 shares of the biotechnology company’s stock after selling 179,891 shares during the quarter. Rice Hall James & Associates LLC’s holdings in BioCryst Pharmaceuticals were worth $14,272,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of BioCryst Pharmaceuticals by 7.7% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 1,288 shares during the period. Royal Bank of Canada lifted its holdings in BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the last quarter. Captrust Financial Advisors lifted its holdings in BioCryst Pharmaceuticals by 7.4% during the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 1,527 shares during the last quarter. Main Management ETF Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company’s stock valued at $1,005,000 after purchasing an additional 1,824 shares during the last quarter. Finally, Wellington Management Group LLP raised its position in shares of BioCryst Pharmaceuticals by 2.6% in the first quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock valued at $685,000 after purchasing an additional 2,291 shares during the period. Institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

BCRX has been the topic of a number of research reports. Cantor Fitzgerald upped their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. HC Wainwright boosted their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 15th. JMP Securities upped their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 15th. Citizens Jmp dropped their target price on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. Finally, Needham & Company LLC decreased their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total value of $166,563.45. Following the sale, the insider owned 398,751 shares of the company’s stock, valued at approximately $3,050,445.15. This trade represents a 5.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 183,453 shares of company stock worth $1,330,965 in the last three months. 5.10% of the stock is owned by corporate insiders.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $7.63 on Friday. The business has a fifty day moving average price of $7.26 and a two-hundred day moving average price of $8.02. The stock has a market capitalization of $1.61 billion, a PE ratio of -152.60, a P/E/G ratio of 0.76 and a beta of 0.91. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The company had revenue of $159.40 million during the quarter, compared to analyst estimates of $162.91 million. During the same period last year, the firm earned ($0.07) EPS. The firm’s revenue for the quarter was up 36.1% compared to the same quarter last year. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.